User login
Key clinical point: Eptinezumab vs placebo demonstrated early, sustained, and clinically meaningful improvements in patient-reported outcomes in patients with chronic migraine and medication-overuse headache.
Major finding: Higher proportions of patients receiving 100/300 mg eptinezumab vs placebo showed ≥6-point reduction in the 6-item Headache Impact Test total score (46.0%/57.1% vs 31.7%) at week 4 and improvements in Patient Global Impression of Change scores (58.5%/67.4% vs 35.8%) and patient-identified most bothersome symptom (57.1%/64.6% vs 29.9%) at week 12, which was sustained until week 24.
Study details: This post hoc analysis of the phase 3 PROMISE-2 trial included a subgroup of 431 patients with chronic migraine and medication-overuse headache who were randomly assigned to receive ≤2 doses of eptinezumab (100/300 mg) or placebo.
Disclosures: The trial was funded by Lundbeck Seattle BioPharmaceuticals, Inc. Three authors declared being current or former employees of Lundbeck or its subsidiaries or a company contracted by H Lundbeck A/S. Several authors reported ties with various sources, including Lundbeck.
Source: Starling AJ et al. Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial. Headache. 2023 (Jan 12). Doi: 10.1111/head.14434
Key clinical point: Eptinezumab vs placebo demonstrated early, sustained, and clinically meaningful improvements in patient-reported outcomes in patients with chronic migraine and medication-overuse headache.
Major finding: Higher proportions of patients receiving 100/300 mg eptinezumab vs placebo showed ≥6-point reduction in the 6-item Headache Impact Test total score (46.0%/57.1% vs 31.7%) at week 4 and improvements in Patient Global Impression of Change scores (58.5%/67.4% vs 35.8%) and patient-identified most bothersome symptom (57.1%/64.6% vs 29.9%) at week 12, which was sustained until week 24.
Study details: This post hoc analysis of the phase 3 PROMISE-2 trial included a subgroup of 431 patients with chronic migraine and medication-overuse headache who were randomly assigned to receive ≤2 doses of eptinezumab (100/300 mg) or placebo.
Disclosures: The trial was funded by Lundbeck Seattle BioPharmaceuticals, Inc. Three authors declared being current or former employees of Lundbeck or its subsidiaries or a company contracted by H Lundbeck A/S. Several authors reported ties with various sources, including Lundbeck.
Source: Starling AJ et al. Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial. Headache. 2023 (Jan 12). Doi: 10.1111/head.14434
Key clinical point: Eptinezumab vs placebo demonstrated early, sustained, and clinically meaningful improvements in patient-reported outcomes in patients with chronic migraine and medication-overuse headache.
Major finding: Higher proportions of patients receiving 100/300 mg eptinezumab vs placebo showed ≥6-point reduction in the 6-item Headache Impact Test total score (46.0%/57.1% vs 31.7%) at week 4 and improvements in Patient Global Impression of Change scores (58.5%/67.4% vs 35.8%) and patient-identified most bothersome symptom (57.1%/64.6% vs 29.9%) at week 12, which was sustained until week 24.
Study details: This post hoc analysis of the phase 3 PROMISE-2 trial included a subgroup of 431 patients with chronic migraine and medication-overuse headache who were randomly assigned to receive ≤2 doses of eptinezumab (100/300 mg) or placebo.
Disclosures: The trial was funded by Lundbeck Seattle BioPharmaceuticals, Inc. Three authors declared being current or former employees of Lundbeck or its subsidiaries or a company contracted by H Lundbeck A/S. Several authors reported ties with various sources, including Lundbeck.
Source: Starling AJ et al. Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial. Headache. 2023 (Jan 12). Doi: 10.1111/head.14434